Picture of BioNTech SE logo

BNTX BioNTech SE Cashflow Statement

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousLarge CapContrarian

Annual cashflow statement for BioNTech SE, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.

2019
December 31st
2020
December 31st
2021
December 31st
2022
December 31st
2023
December 31st
Period Length:12 M12 M12 M12 M12 M
Source:20-F20-F20-F20-F20-F
Standards:
IFRS
IFRS
IFRS
IFRS
IFRS
Status:FinalFinalFinalFinalFinal
Net Income/Starting Line-179-14615,04612,9541,186
Depreciation
Non-Cash Items31.1188-32.6248-577
Unusual Items
Equity in Net Earnings/Losses
Other Non-Cash Items
Changes in Working Capital-84.1-94.9-14,1992524,579
Change in Accounts Receivable
Change in Inventories
Change in Accounts Payable
Other Operating Cash Flow
Cash from Operating Activities-199-13.589013,5775,371
Capital Expenditures-71.1-85.4-154-363-706
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items-6.04-59.4-412328-6,249
Acquisition of Business
Sale of Business
Sale of Fixed Assets
Sale/Maturity of Investment
Purchase of Investments
Other Investing Cash Flow
Cash from Investing Activities-77.1-145-566-35.3-6,955
Total Cash Dividends Paid
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities38389594.2-1,419-779
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash10869148312,182-2,211